XML 36 R26.htm IDEA: XBRL DOCUMENT v3.19.1
Basis of Presentation (Tables)
9 Months Ended
Mar. 31, 2019
Accounting Policies [Abstract]  
Adoption of New Revenue Recognition Standard Revenue Impacted Previously Reported

Adoption of new revenue recognition standard impacted the Company’s previously reported results as follows:

 

 

Three months ended

 

Nine months ended

 

 

March 31, 2018

 

March 31, 2018

 

 

As Previously Reported

 

ASC606 Adjustments

 

As Restated

 

As Previously Reported

 

ASC606 Adjustments

 

As Restated

 

Consolidated Statements of Operations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

$

191.1

 

$

(8.0

)

$

183.1

 

$

571.7

 

$

(21.9

)

$

549.8

 

Selling, general and administrative expense

 

115.1

 

 

(7.2

)

 

107.9

 

 

345.5

 

 

(23.2

)

 

322.3

 

Income tax provision

 

4.5

 

 

(0.2

)

 

4.3

 

 

(17.0

)

 

0.3

 

 

(16.7

)

Net Income attributable to Myriad Genetics, Inc. stockholders

 

9.7

 

 

(0.6

)

 

9.1

 

 

118.0

 

 

0.9

 

 

118.9

 

Earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.14

 

$

(0.01

)

$

0.13

 

$

1.71

 

$

0.01

 

$

1.72

 

Diluted

$

0.13

 

$

(0.01

)

$

0.13

 

$

1.66

 

$

 

$

1.66

 

 

 

Nine months ended

 

 

March 31, 2018

 

 

As Previously Reported

 

ASC606 Adjustments

 

As Restated

 

Consolidated Statements of Cash Flows:

 

 

 

 

 

 

 

 

 

Net Income attributable to Myriad Genetics, Inc. stockholders

 

118.0

 

 

0.9

 

$

118.9

 

Trade Accounts Receivable

 

(42.3

)

 

(27.9

)

 

(14.4

)

 

 

June 30, 2018

 

 

As Previously Reported

 

ASC606 Adjustments

 

As Restated

 

Consolidated Balance Sheet:

 

 

 

 

 

 

 

 

 

Trade accounts receivable

$

98.3

 

$

1.2

 

$

99.5

 

Retained Earnings

 

52.9

 

 

1.2

 

 

54.1